Abstract: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.

Abstract: The invention relates to polymers comprising indenofluorene units or derivatives thereof, organic semiconductor (OSC) materials comprising them, their use in electronic or electrooptical devices, and devices comprising said polymers or materials.

Abstract: The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presence of a protonic acid or lewis acid with a suitable solvent. A, B, C have the meaning as described in the specification.

Abstract: The invention relates to novel mesogenic dimeric compounds which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the dimers, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, Alk and D have the meanings indicated in claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds, characterized in that it comprises one or more compounds of the formula I in which R1, X1, L1-5 have the meanings indicated in Claim 1, and to the use thereof for electro-optical purposes, in particular TN monitor applications.

Abstract: The present invention relates to novel benzimidazole-dihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, to processes for the preparation thereof and to the use thereof in therapy, especially for the treatment of diabetes.

Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising in each case one or more compounds of the formula I in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays containing these media, especially to active-matrix displays and in particular to TN, IPS and FFS displays.

Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising a dielectrically positive component, component A, comprising a dielectrically positive compound of the formula I in which the parameters have the meaning indicated in the specification, and optionally a second dielectrically positive component, component B, comprising one or more dielectrically positive compounds having a dielectric anisotropy of great than 3, and optionally a dielectrically neutral component, component C, and to liquid-crystal displays containing these media, especially active-matrix displays and in particular TN, IPS and FFS displays.

Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.

Abstract: The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I wherein R1, R2, R3, R6, R7 and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer.

Abstract: Described are pyridopyrazinone derivatives of formula (I), wherein X, Y, Z, W, A and R1 are as defined in claim 1, as insulin secretion stimulators. Also described is the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.

Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.

Abstract: The present invention relates to an electro-optical light-modulation element of the FFS type, and to electro-optical displays and display systems, such as, for example, television screens and computer monitors, which contain elements of this type. The light-modulation elements according to the invention contain a liquid-crystalline modulation medium which has optimised elastic constants and are distinguished, in particular, by high contrast and/or optimised transmission in addition to good contrast, a low viewing-angle dependence, short response times and low addressing voltages. The present invention likewise relates to the liquid-crystalline modulation media used in the electro-optical light-modulation elements.

Abstract: The invention relates to liquid-crystalline compounds of the formula I in which R1, R2, A1, A2, A3, A4, Z1, Z2, Z3, V, a, b and c have the meanings indicated in Claim 1, and to liquid-crystalline media comprising at least one compound of the formula I, and to electro-optical displays containing a liquid-crystalline medium of this type.

Abstract: The invention relates to tricyclic aromatics of the general formula I in which A1, A2, A3, A4, Q1-Q2, R1, R2, X1, X2, X3, Z1, Z2, Z3, Z4, q, r, s, t and u have the meaning indicated, and to the use thereof as components of liquid-crystalline media and to an electro-optical display element containing same.

Abstract: This invention relates to coloured polymer particles preferably with surface functionality for charge retention, a process for their preparation, the use of these particles for the preparation of an electrophoretic device, colour electrophoretic displays comprising such particle, and new water-soluble dyes.

Abstract: The present invention relates to liquid-crystal (LC) media for use in LC displays of the PS (polymer stabilised) or PSA (polymer sustained alignment) type.

Abstract: The invention relates to a liquid-crystalline medium containing one or more compounds of the formula I and one or more compounds selected from the group of the compounds of the formula IA to IE in which R0, R1, R2, X1, X2, A1, Z1, m, p, q, v have the meanings indicated in claim 1, and to the use thereof in electro-optical liquid-crystal displays.

Abstract: Compounds of the formula I, in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.